How Tirzepatide May Raise Heart Rate

A 2026 laboratory study offers a direct cellular explanation for the small heart-rate increase seen with tirzepatide. In pacemaker cells made from human induced pluripotent stem cells and in three-dimensional cardiac organoids, tirzepatide increased spontaneous beating by changing cyclic AMP and calcium signalling^[1][2]. No patient was treated in this experiment. The result explains a possible mechanism; it does not show that tirzepatide treats a slow heart rhythm or predicts an individual's pulse.

The clinical observation is already documented in prescribing information. Across placebo-controlled adult trials, the current US Mounjaro label reports a mean heart-rate increase of 2 to 4 beats per minute with tirzepatide, compared with 1 beat per minute on placebo. The label says the clinical relevance of the increase is uncertain^[3].

How the researchers built a pacemaker model

The sinoatrial node is the heart's natural pacemaker. Its specialized cells generate the electrical rhythm that starts each heartbeat. Researchers produced sinoatrial-node-like cells from human induced pluripotent stem cells, which are laboratory-grown cells that can be directed toward a chosen cell type. They confirmed the cells with established sinoatrial-node markers^[2].

They then combined those pacemaker cells with cardiac fibroblasts at a nine-to-one ratio to make three-dimensional sinoatrial-node cardiac organoids. An organoid is a small laboratory tissue model, not a whole heart. These organoids beat spontaneously at about 100 beats per minute and responded as expected to dobutamine, which can increase rate, and ivabradine, which slows sinoatrial-node firing^[2]. Those checks showed that the model had recognizable pacemaker behavior before tirzepatide was tested.

Tirzepatide increased beating in the model

At a concentration of 100 nanomolar, tirzepatide increased the organoids' spontaneous beating rate by 8.59%, with a reported error of plus or minus 1.88%. Blocking both the GLP-1 and GIP receptors weakened that response, supporting involvement of the two receptors targeted by tirzepatide. Propranolol, a beta blocker, also blunted the rate increase in the acute experiment^[2].

An 8.59% change in an organoid is not equivalent to an 8.59% increase in a person's heart rate. Concentration at the cells, drug exposure over time, nervous-system input, hormones, and the rest of the cardiovascular system differ between this model and a living patient. The study connects a drug to pacemaker-cell behavior under controlled conditions. It does not provide a conversion from the laboratory result to a clinical pulse change.

The cAMP and calcium mechanism

GLP-1 and GIP receptors can signal through a protein called G-alpha-s, which raises cyclic adenosine monophosphate, usually shortened to cAMP. The researchers used fluorescent biosensors to measure cAMP in different parts of the pacemaker cells. Tirzepatide increased the signal at the plasma membrane and at the sarcoplasmic reticulum, the cell compartment that stores calcium. The response was stronger at the sarcoplasmic reticulum^[2].

Imaging placed both incretin receptors near phospholamban, a protein that helps regulate calcium movement into the sarcoplasmic reticulum. Tirzepatide increased phospholamban phosphorylation at serine 16 and shortened calcium-transient decay, consistent with faster calcium recycling. Blocking the GLP-1 and GIP receptors suppressed the phosphorylation response^[2]. The authors propose that localized cAMP activates protein kinase A, which modifies phospholamban and speeds the calcium cycle that supports pacemaker firing.

That sequence is biologically coherent, but it remains a model-derived mechanism. The cells came from previously established, de-identified human stem-cell lines. They were not sinoatrial-node cells freshly sampled from people taking tirzepatide, and the organoids did not include the full autonomic nervous system that adjusts heart rate from moment to moment.

What this means for patients

The label reports dose-group differences in episodes of sinus tachycardia accompanied by a rise of at least 15 beats per minute from baseline. Rates were 4.3% on placebo and 4.6% on Mounjaro 5 mg, rising to 5.9% on 10 mg and 10% on 15 mg. The same label still describes the clinical relevance of heart-rate increases as uncertain^[3]. The laboratory paper helps explain how a direct pacemaker-cell effect could contribute. It does not determine who will experience it or whether another cause is responsible for a symptom.

Readers can use our tirzepatide overview for the broader clinical evidence and the tirzepatide regulation tracker for approved-product status. A racing, unusually slow, or irregular heartbeat deserves clinical assessment, especially with fainting, chest pain, or shortness of breath. This article does not advise changing a prescription.

What we do not know yet

The study does not show whether the same intracellular sequence dominates in an intact adult human sinoatrial node. It cannot separate direct pacemaker effects from changes driven by the nervous system or by weight loss in patients. It also does not establish whether the small mean increase recorded in trials creates harm, has no practical consequence, or differs in people with rhythm disorders.

Follow-up work could test patient-specific stem-cell lines, longer exposure, clinically matched concentrations, and models that include autonomic inputs. Clinical studies would need continuous or repeated rhythm measurements and prespecified outcomes. For now, the paper supplies a plausible cellular mechanism for an observed label finding, not a new cardiac indication for tirzepatide.